FDA issues warning on anaphylaxis risk with MS drugs

The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction. 

Advertisement

This severe reaction can occur at any time during treatment, including months or years after starting the drug, according to a Jan. 22 news release from the agency. 

Symptoms of anaphylaxis typically develop within an hour of injection and can include wheezing, difficulty breathing, swelling of the face or throat and hives. In some cases, the reaction can lead to hospitalization or death. 

While the immediate post-injection reaction is common among patients using glatiramer acetate, anaphylaxis is much rarer but more severe. The FDA urges both patients and healthcare professionals to be aware of these symptoms and to act quickly if they appear. 

Advertisement

Next Up in Pharmacy

  • The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

  • From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

  • In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

Advertisement

Comments are closed.